- Trials with a EudraCT protocol (314)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
314 result(s) found for: Everolimus.
Displaying page 10 of 16.
EudraCT Number: 2012-004860-22 | Sponsor Protocol Number: IJB-BCTL:20120306 | Start Date*: 2014-01-16 | |||||||||||
Sponsor Name:Institute Jules Bordet | |||||||||||||
Full Title: The [PEARL] Study : Pet imaging as a biomarker of Everolimus Added value in hormone Refractory postmenopausaL women | |||||||||||||
Medical condition: Locally advanced or metastatic endocrine receptor positive and HER2 negative breast cancer refractory to non-steroidal aromatase inhibitors (NSAI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006181-28 | Sponsor Protocol Number: CRAD001LFR08 | Start Date*: 2009-04-27 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer | |||||||||||||
Medical condition: Patients who have metastatic papillary cancer of the kidney and have not received prior systemic treatment for their metastatic RCC. This multicenter international trial will enroll a maximum of 60... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000541-38 | Sponsor Protocol Number: CRAD001A2403 | Start Date*: 2004-09-27 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in addition to Certican 61668; and Steroids in de novo Heart Transplant Recipients. | |||||||||||||
Medical condition: Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. It should be used in combination with ciclosporin for mic... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003255-20 | Sponsor Protocol Number: CRAD001C2241 | Start Date*: 2006-11-23 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A single arm, multicenter phase II study of RAD001 in patients with metastatic colorectal adenocarcinoma whose cancer has progressed despite prior therapy with an anti-EGFR antibody (if appropriate... | |||||||||||||
Medical condition: metastatic colorectal adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011623-31 | Sponsor Protocol Number: AGO/2009/003 | Start Date*: 2009-04-24 |
Sponsor Name:University Hospital Ghent | ||
Full Title: Individually adapted immunosuppression in de novo renal transplantation based on immune function monitoring: a prospective randomised study Extension study: The impact of magnesium supplementation ... | ||
Medical condition: de novo renal transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007153-13 | Sponsor Protocol Number: 03-2008 | Start Date*: 2009-03-12 | |||||||||||
Sponsor Name:I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY | |||||||||||||
Full Title: An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment | |||||||||||||
Medical condition: Patients with neuroendocrine tumours | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020067-20 | Sponsor Protocol Number: 2010/23 | Start Date*: 2010-08-02 |
Sponsor Name:Hôpital FOCH | ||
Full Title: A multicentre phase II trial to determine the efficacy of RAD 001 (everolimus, Afinitor®) as second line therapy in patients with transitional cell carcinoma (TCC) of the urothelium which failed or... | ||
Medical condition: Patients who have metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium who failed prior systemic chemotherapy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004575-21 | Sponsor Protocol Number: UCL-ONCO008-02 | Start Date*: 2008-10-23 |
Sponsor Name:Cliniques Universitaires St Luc | ||
Full Title: A single arm, multicenter, phase II trial of RAD001 as monotherapy in the palliative treatment of patient with locally advanced or metastatic transitional cell carcinoma after failure of platinum-b... | ||
Medical condition: Palliative patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004332-79 | Sponsor Protocol Number: GINECO-BR105 | Start Date*: 2007-07-10 |
Sponsor Name:ARCAGY | ||
Full Title: "Essai multicentrique de phase II randomisé évaluant la tolérance et l'efficacité du tamoxifène seul versus association Tamoxifène-RAD001 (Everolimus), chez les patientes atteintes de cancer du sei... | ||
Medical condition: metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003672-19 | Sponsor Protocol Number: EVERINA | Start Date*: 2006-10-24 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
Full Title: NON APPLICABILE | |||||||||||||
Medical condition: Immunosoppressive therapy in liver transplanted patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016176-78 | Sponsor Protocol Number: 2009-016176-78 | Start Date*: 2010-02-08 | |||||||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA | |||||||||||||||||||||||
Full Title: Terapy with everolimus in liver transplant. | |||||||||||||||||||||||
Medical condition: liver transplant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002387-24 | Sponsor Protocol Number: CHU-P2011-05 | Start Date*: 2013-07-02 |
Sponsor Name:CHU Angers | ||
Full Title: Dyva-AAGG: Dysfonction vasculaire micro et macro vasculaire induite par les traitements anti-angiogéniques : Identification de nouveaux marqueurs pronostics | ||
Medical condition: cancer : rein, digestifs, pancréas | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004510-99 | Sponsor Protocol Number: 012017POEM | Start Date*: 2017-02-21 | |||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: PERFORMANCE OF BIORESORBABLE POLYMER-COATED EVEROLIMUS-ELUTING SYNERGY® STENT IN PATIENTS AT HIGH BLEEDING RISK UNDERGOING PERCUTANEOUS CORONARY REVASCULARIZATION FOLLOWED BY 1-MONTH DUAL ANTIPLATE... | |||||||||||||
Medical condition: Coronary artery disease with high-bleeding risk (HBR) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008754-23 | Sponsor Protocol Number: CILT08 | Start Date*: 2009-12-16 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Göttingen | ||||||||||||||||||||||||||||
Full Title: A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free de-novo Immunosuppression after Liver Transplantation. | ||||||||||||||||||||||||||||
Medical condition: Patients with renal dysfunction undergoing liver transplantation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005834-19 | Sponsor Protocol Number: GBG44 | Start Date*: 2007-10-27 |
Sponsor Name:GBG Forschungs GmbH | ||
Full Title: A phase III trials program exploring the integration of Bevacizumab, Everolimus (RAD001), and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer | ||
Medical condition: breast cancer, primary systemic therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000974-22 | Sponsor Protocol Number: C06-46 | Start Date*: 2008-01-23 | |||||||||||
Sponsor Name:Inserm | |||||||||||||
Full Title: Essai thérapeutique de phase II séquentiel non randomisé non contrôlé, multicentrique de traitement par everolimus de la maladie de Kaposi classique ou endémique. | |||||||||||||
Medical condition: Maladie de Kaposi classique ou endémique | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000701-21 | Sponsor Protocol Number: CRAD001C2222 | Start Date*: 2004-11-25 |
Sponsor Name:Novartis Services AG | ||
Full Title: A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole (Femara®) as preoperative therapy of primary breast cancer in postmenop... | ||
Medical condition: Systemic treatment for breast cancer given when the primary tumors are still present in situ within the breast can result in large tumors being down-staged, which can allow for more conservative su... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011008-43 | Sponsor Protocol Number: CRAD001AIT16 - EVERHEART | Start Date*: 2009-06-24 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: Early vs.delayed EVERolimus in de novo HEART transplant recipients: optimozation of the safety/efficacy profile (EVERHEART Study) | |||||||||||||
Medical condition: de novo heart transplant patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003002-10 | Sponsor Protocol Number: GINECO-EN101 | Start Date*: 2007-10-09 | |||||||||||
Sponsor Name:ARCAGY-GINECO | |||||||||||||
Full Title: A multicentre phase II study, estimating the efficiency and the tolerance of RAD001 (Everolimus) , in patients with endometrial metastatic cancer resistant to a first line of chemotherapy | |||||||||||||
Medical condition: Endometrial metastatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001595-20 | Sponsor Protocol Number: CRAD001J2102 | Start Date*: 2006-11-23 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A phase Ib study investigating the combination of RAD001 with trastuzumab and vinorelbine in patients with HER2- overexpressing metastatic breast cancer | |||||||||||||
Medical condition: HER2 overexpressing metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
